- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
Novo Nordisk (NVO) stock rating was increased to 'buy' at Deutsche Bank.
Novo Nordisk (NVO) CEO Lars Rebien Sorensen will leave the company as it faces continued pressure in the insulin market.